Chronic inflammatory demyelinating polyneuropathy associated with podocytopathy: a clinical case with literature review

Chronic imflammatory demyelinating polyneuropathy (CIPD) is a heterogenous group of disimmune polyneuropathies, characterised by progressive or relapsing-remitting disease course, with electrophysiologically and pathomorphologically detected peripheral nerve demyelination. Immunotherapy is considered reasonable in CIDP. CIDP associated with antibodies against nodo-paranodal proteins, namely, NF155, CNTN1, Contactin associated protein has been described amongst the rare atypical CIDP subtypes. The detection of antibodies against nodo-paranodal proteins might have a predictive value for a more severe disease course with resistance to corticosteroid and/or IVIG treatment. Herein we report a case of severe relapsing-remitting CIDP, characterized by respiratory muscle weakness requiring assisted ventilation, with a previous history of proteinuria, later also diagnosed with Minimal change disease (MCD).

1. Stino AM, Naddaf E, Dyck PJ, Dyck PJB. Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach. Muscle Nerve. 2021; 63 (2): 157-169. https://doi.org/10.1002/mus.27046

2. Van den Bergh PY, Hadden RD, Bouche P. et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision [published correction appears in Eur. J. Neurol. 2011 May; 18 (5): 796]. Eur. J. Neurol. 2010; 17 (3): 356-363. https://doi.org/10.1111/j.1468–1331.2009.02930.x

3. Querol L, Nogales-Gadea G, Rojas-Garcia R. et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014; 82 (10): 879-886. https://doi.org/10.1212/WNL.0000000000000205

4. Christiaan Fokke, Bianca van den Berg, Judith Drenthen, Christa Walgaard, Pieter Antoon van Doorn, Bart Casper Jacobs, Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria, Brain. 2014 Jan; 137 (1): 33-43. https://doi.org/10.1093/brain/awt285

5. Walgaard C., Lingsma H.F., Ruts L., Drenthen J., van Koningsveld R., Garssen M.J.P., van Doorn P.A., Steyerberg E.W. and Jacobs B.C. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010; 67: 781-787. https://doi.org/10.1002/ana.21976

6. Menon D, Katzberg HD, Bril V. Treatment Approaches for Atypical CIDP. Front Neurol. 2021; 12: 653734. Published 2021 Mar 15. https://doi.org/10.3389/fneur.2021.653734

7. Suponeva N.A., Grishina D.A., Ryabinkina Y.V., Arestova A.S., Melnik E.A., Tumilovich T.A. Chronic inflammatory demyelinating polyneuropathy with an acute onset. Clinical case. Terapevticheskii arkhiv. 2022; 94 (4): 544-551. https://doi.org/10.26442/00403660.2022.04.201457

8. Kanbayashi T, Sonoo M. Brain Nerve. 2015; 67 (11): 1388-1396. https://doi.org/10.11477/mf.1416200311

9. Bertelli R, Bonanni A, Di Donato A, Cioni M, Ravani P, Ghiggeri GM. Regulatory T cells and minimal change nephropathy: in the midst of a complex network. Clin. Exp. Immunol. 2016; 183 (2): 166-174. https://doi.org/10.1111/cei.12675

10. Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol. Neurosurg. Psychiatry. 2015; 86 (9): 973-985. https://doi.org/10.1136/jnnp2014–309697

11. Querol L, Rojas-García R, Diaz-Manera J. et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol. Neuroimmunol Neuroinflamm. 2015; 2 (5): e149. Published 2015 Sep 3. https://doi.org/10.1212/NXI.0000000000000149

12. Devaux JJ, Miura Y, Fukami Y. et al. Neurofascin155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016; 86 (9): 800-807. https://doi.org/10.1212/WNL.0000000000002418

13. Xue C, Yang B, Xu J. et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clin Kidney J. 2020; 14 (4): 1042-1054. Published 2020 Nov 21. https://doi.org/10.1093/ckj/sfaa191

14. Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol. Dial. Transplant. 2008; 23 (1): 377-380. https://doi.org/10.1093/ndt/gfm592

15. Bunschoten C, Jacobs BC, van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019; 18 (8): 784–794. https://doi.org/10.1016/S1474-4422 (19) 301449

16. Khadilkar SV, Kamat S, Patel R. Nodo-paranodopathies: Concepts, Clinical Implications, and Management. Ann Indian Acad. Neurol. 2022; 25 (6): 1001-1008. https://doi.org/10.4103/aian.aian_382_22

17. Fehmi J, Davies AJ, Walters J. et al. IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality. J. Neurol. Neurosurg. Psychiatry. 2021; 92 (10): 1089-1095. https://doi.org/10.1136/jnnp2021-326343

18. Uncini A. Autoimmune nodo-paranodopathies 10 years later: Clinical features, pathophysiology and treatment. J. Peripher. Nerv. Syst. 2023; 28 Suppl 3: S23-S35. https://doi.org/10.1111/jns.12569

19. Iijima M. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy patients with antibodies against paranodal proteins. Clin. Exp. Neuroimmunol. 2020; 11: 94-100. https://doi.org/10.1111/cen3.12590

20. Martín-Aguilar L, Lleixà C, Pascual-Goñi E. Autoimmune nodopathies, an emerging diagnostic category. Curr. Opin. Neurol. 2022; 35 (5): 579-585. https://doi.org/10.1097/WCO.0000000000001107

21. Remiche G, Monteiro MLS, Catalano C. et al. Rituximab Responsive Relapsing-Remitting IgG4 Anticontactin 1 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Associated with Membranous Nephropathy: A Case Description and Brief Review. J. Clin. Neuromuscul. Dis. 2022; 23 (4): 219-226. https://doi.org/10.1097/CND.0000000000000395

22. Iijima M. Autoimmune nodopathy. Clin. Exp. Neuroimmunol. 2024; 15 (2): 74-81. https://doi.org/10.1111/cen3.12791

23. Shimizu S, Iijima M, Fukami Y. et al. Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Res. Protoc. 2020; 9 (4): e17117. Published 2020 Apr 1. https://doi.org/10.2196/17117

24. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100 (4S): S1-S276. https://doi.org/10.1016/j.kint.2021.05.021.